Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™)

Imatinib mesylate (Gleevec™, STI571), a selective inhibitor of BCR-ABL, c-Kit, and platelet-derived factor receptor, has been used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors. Although its use has been associated with various adverse cutaneous reactions, pityriasi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Ah Young, Kim, Dae Hun, Im, Myung, Lee, Young, Seo, Young Joon, Lee, Jeung Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Dermatological Association; The Korean Society for Investigative Dermatology 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3276797/
https://www.ncbi.nlm.nih.gov/pubmed/22346278
http://dx.doi.org/10.5021/ad.2011.23.S3.S360
Descripción
Sumario:Imatinib mesylate (Gleevec™, STI571), a selective inhibitor of BCR-ABL, c-Kit, and platelet-derived factor receptor, has been used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors. Although its use has been associated with various adverse cutaneous reactions, pityriasis rosea-like drug eruptions are rare. Here, we report a case of pityriasis rosea-like drug eruption that developed following the administration of imatinib mesylate to treat CML.

Ejemplares similares